top of page

Description

 

Non-PVC IV bags are intravenous bags which do not comprise polyvinyl chloride as a material. Since, PVC material can release hazardous chemicals, when in contact with the fluids such as di-2-ethyl hexyl phthalate (DEHP). While, non-PVC bags are made up of materials such as polyethylene, polypropylene, copolyester ether and ethylene vinyl acetate (EVA). These bags are widely used in several healthcare settings such as hospitals, clinics, and emergency medical services. The global non-PVC IV bags market is projected to grow in the coming years, due to the various factors such as rising awareness of the possible risks related to PVC, surging demand for safer and more sustainable medical devices, and advances in technology which make non-PVC materials more cost-effective and easier to manufacture. On the other hand the factors such as limited awareness regarding the benefits of the non-PVC IV bags may restrain the market growth. The Non-PVC IV bags market is likely to grow at a rate of 6.4% CAGR by 2027.

Based on Product Type

Single Chamber
Multi Chamber

Based on Material Type

Polypropylene IV Bag
Polyethylene IV Bag
Others

Based on End User

Hospitals
Ambulatory Surgical Centers
Others

Based on Region

North America
Europe
Asia Pacific
Rest of the World

As in the market for product type is divided into Single Chamber and Multi Chamber. In which, the single chamber segment is projected to lead the market growth. The usage of single-chamber IV bags is increasing currently and is anticipated to remain in the future as IV bags have started other IV containers. The advent of non-PVC materials has driven the replacement of glass containers with plastic bags due to the advantages such as transportation, ease of handling and disposal. Drip bags, irrigation fluids, and sterile water are also commonly used intravenous solutions. Henceforth, single-chamber bags are commonly used and the segment is expected to grow over the estimated period.

The material type segment is categorized into Polypropylene IV Bag, Polyethylene IV Bag and Others. Where, the polypropylene IV bags segment is dominating the market and is also likely to remain dominant over the non-PVC IV bags market forecast period. This can be ascribed to the requirement for enhanced patient safety, increased environmental sustainability, provision of improved clinical outcomes cost-effectiveness and regulatory pressure.

As per the end users the market is segmented as Hospitals, Ambulatory Surgical Centers and Others. The hospital end user segment is likely to hold the major share in the market growth. This is due to the rise in concerns regarding the safety and environmental impact of PVC.

The geographical market is divided into North America, Europe, Asia Pacific and Rest of the World. As the North America region In the United States, strict regulations aimed at enhance the patient safety which have surged the demand for non-PVC IV containers, which offer patient treatment without risking harm. Further, the demand for IV bags has increased majorly as the prevalence of stomach cancer has increased over the past few years in United States.

Global market is significantly driven by the growing incidences of hospital-acquired infections (HAIs) among the population. Along with the rising number of patients requiring intravenous antibiotics across healthcare facilities, this has given a boost to the demand for non-PVC IV bags. Moreover, the rising adoption of single-chambered non-PVC IV bags in IV drips and other mixtures owing to their easy of management, transportation, and disposal is highly leading to the product sales across the world. In addition to this, the surging number of point-of-care (POC) facilities across the world and the preference for home care setups, especially for the old population, is favorably impacting the global market growth.

The non-PVC IV bags market research report presents analysis and overview of the key market competitors which include JW Life Science, Shanghai Solve Care Co Ltd., ANGIPLAST PVT. LTD, B. Braun Melsungen AG, Baxter, PolyCine GmbH, Pfizer, Inc (Hospira), Fresenius Kabi AG, RENOLIT, and Sealed Air.

Henceforth, the inclination towards non-PVC IV bags represents a vital trend in the healthcare industry, since it reflects an increasing awareness of the requirement to prioritize patient safety and environmental sustainability in the development and use of medical devices.

Impacting factors which are fostering the demand and latest trends running in the market are provided in the report.
Non-PVC IV bags market forecast for global market split into segments such as region, substrates and applications are mentioned in the study.
This study further presents the analysis of new product launches, mergers and acquisitions and research and developments of the key competitors.
The penetration of non-PVC IV bags market across the four geographical regions is also elucidated in this report.

 

Non-PVC IV Bags Market Forecast up to 2028

4 500,00$Prix
  • Table of Contents

    1. Executive Summary
    2. Industry Outlook

    2.1. Industry Overview
    2.2. Industry Trends
    3. Market Snapshot
    3.1. Market Definition
    3.2. Market Outlook
    3.2.1. Porter Five Forces
    3.3. Related Markets
    4. Market characteristics
    4.1. Market Overview
    4.2. Market Segmentation
    4.3. Market Dynamics
    4.3.1. Drivers
    4.3.2. Restraints
    4.3.3. Opportunities
    4.4. DRO - Impact Analysis
    5. Product Type: Market Size & Analysis
    5.1. Overview
    5.2. Single Chamber
    5.3. Multi Chamber
    6. Material Type: Market Size & Analysis
    6.1. Overview
    6.2. Polypropylene IV Bag
    6.3. Polyethylene IV Bag
    6.4. Others
    7. End User: Market Size & Analysis
    7.1. Overview
    7.2. Hospitals
    7.3. Ambulatory Surgical Centers
    7.4. Others
    8. Geography: Market Size & Analysis
    8.1. Overview
    8.2. North America
    8.3. Europe
    8.4. Asia Pacific
    8.5. Rest of the World
    9. Competitive Landscape
    9.1. Competitor Comparison Analysis
    9.2. Market Developments
    9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
    9.2.2. Product Launches and execution
    10. Vendor Profiles
    10.1. JW Life Science
    10.1.1. Overview
    10.1.2. Financial Overview
    10.1.3. Product Offerings
    10.1.4. Developments
    10.1.5. Business Strategy
    10.2. Shanghai Solve Care Co Ltd.
    10.2.1. Overview
    10.2.2. Financial Overview
    10.2.3. Product Offerings
    10.2.4. Developments
    10.2.5. Business Strategy
    10.3. ANGIPLAST PVT. LTD
    10.3.1. Overview
    10.3.2. Financial Overview
    10.3.3. Product Offerings
    10.3.4. Developments
    10.3.5. Business Strategy
    10.4. B. Braun Melsungen AG
    10.4.1. Overview
    10.4.2. Financial Overview
    10.4.3. Product Offerings
    10.4.4. Developments
    10.4.5. Business Strategy
    10.5. Baxter
    10.5.1. Overview
    10.5.2. Financial Overview
    10.5.3. Product Offerings
    10.5.4. Developments
    10.5.5. Business Strategy
    10.6. PolyCine GmbH
    10.6.1. Overview
    10.6.2. Financial Overview
    10.6.3. Product Offerings
    10.6.4. Developments
    10.6.5. Business Strategy
    10.7. Pfizer, Inc.
    10.7.1. Overview
    10.7.2. Financial Overview
    10.7.3. Product Offerings
    10.7.4. Developments
    10.7.5. Business Strategy
    10.8. Fresenius Kabi AG
    10.8.1. Overview
    10.8.2. Financial Overview
    10.8.3. Product Offerings
    10.8.4. Developments
    10.8.5. Business Strategy
    10.9. RENOLIT
    10.9.1. Overview
    10.9.2. Financial Overview
    10.9.3. Product Offerings
    10.9.4. Developments
    10.9.5. Business Strategy
    10.10. Sealed Air
    10.10.1. Overview
    10.10.2. Financial Overview
    10.10.3. Product Offerings
    10.10.4. Developments
    10.10.5. Business Strategy
    11. Analyst Opinion
    12. Annexure

    12.1. Report Scope
    12.2. Market Definitions
    12.3. Research Methodology
    12.3.1. Data Collation and In-house Estimation
    12.3.2. Market Triangulation
    12.3.3. Forecasting
    12.4. Report Assumptions
    12.5. Declarations
    12.6. Stakeholders
    12.7. Abbreviations
  • LinkedIn
  • Twitter
  • Twitter
  • Linkedin
bottom of page